目的 探討阿伐他汀對(duì)慢性阻塞性肺疾?。–OPD）合并肺動(dòng)脈高壓患者血清炎癥因子水平、肺功能和右心室重塑的影響。方法 將寶雞市中心醫(yī)院自2013年12月-2016年12月收治的COPD合并肺動(dòng)脈高壓患者106例作為研究對(duì)象，隨機(jī)分為研究組和對(duì)照組，各53例，對(duì)照組患者給予常規(guī)基礎(chǔ)治療，研究組患者在對(duì)照組治療的基礎(chǔ)上加用阿伐他汀進(jìn)行治療，連續(xù)治療3個(gè)月。檢測患者肺功能、右心室重塑功能及炎癥因子相關(guān)指標(biāo)，評(píng)價(jià)兩組患者的臨床療效。結(jié)果 研究組患者臨床總有效率為94.34%，對(duì)照組為79.25%，組間比較差異顯著（P<0.05）。治療前兩組患者第一秒用力呼氣容積（FEV₁）、用力肺活量（FVC）水平比較差異不顯著，治療后研究組患者FVC和FEV₁水平顯著高于對(duì)照組（P<0.05）。與治療前比較，兩組治療后舒張末期左心室內(nèi)徑（LVID）、舒張末期左心室后壁厚度（LVPW）、三尖瓣最大反流速度（TRV_max）、右室射血分?jǐn)?shù)（RVEF）均升高，舒張末期右心室內(nèi)徑（RVAD）降低，差異顯著（P<0.05）；治療后研究組指標(biāo)LVID、LVPW、TRV_max、RVEF高于對(duì)照組，RVAD低于對(duì)照組，差異顯著（P<0.05）。治療前兩組患者C反應(yīng)蛋白（CRP）、內(nèi)皮素（ET）和白細(xì)胞介素（IL-6）水平比較差異不顯著，治療后研究組患者CRP、ET、IL-6水平降低程度顯著優(yōu)于對(duì)照組（P<0.05）。結(jié)論 阿伐他汀有效改善COPD聯(lián)合肺動(dòng)脈高壓患者血清炎癥因子水平、肺功能及右心室重塑的影響，臨床效果顯著，可推廣使用。

Objective To investigate the effect of atorvastatin on serum levels of inflammatory cytokines, pulmonary function and right ventricular remodeling in patients with chronic obstructive pulmonary disease (COPD) complicated with pulmonary hypertension. Methods From December 2013 to December 2016, 106 patients with COPD complicated with pulmonary hypertension were randomly divided into treatment and control groups, each with 53 cases. Patients in control group were treated with routine basic therapy for three months, and patients in treatment group were treated with atorvastatin on the basis of control group. The pulmonary function, right ventricular remodeling function and inflammatory factors were detected, and the clinical efficacy of two groups was evaluated. Results The total effective rate was 94.34% in the treatment group and 79.25% in the control group, difference between the two groups was significant (P<0.05). The levels of FEV₁ and FVC were not significantly different between two groups before treatment. The levels of FVC and FEV₁ in treatment group were significantly higher than those in the control group after treatment (P<0.05). After treatment, the LVED, LVPW, TRV_max and RVEF of treatment group were significantly higher than those of control group (P<0.05), and the difference was statistically significant. Compared with before treatment, LVID, LVPW and TRV_max were increased, RVAD decreased, and the difference was statistically significant (P<0.05). The levels of CRP, ET and IL-6 in the treatment group were significantly lower than those in the control group (P<0.05), and difference was statistically significant. Conclusion The effect of atorvastatin on serum inflammatory factors, pulmonary function and right ventricular remodeling in patients with COPD combined with pulmonary hypertension is significant and can be popularized.